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Abstract
Background: Malaria Rapid Diagnostic Tests (RDTs) are widely used to diagnose malaria. The present study
evaluated a new RDT, the Clearview
® Malaria pLDH test targeting the pan-Plasmodium antigen lactate
dehydrogenase (pLDH).
Methods: The Clearview
® Malaria pLDH test was evaluated on fresh samples obtained in returned international
travellers using microscopy corrected by PCR as the reference method. Included samples were Plasmodium
falciparum (139), Plasmodium vivax (22), Plasmodium ovale (20), Plasmodium malariae (7), and 102 negative.
Results: Overall sensitivity for the detection of Plasmodium spp was 93.2%. For P. falciparum, the sensitivity was
98.6%; for P. vivax, P. ovale and P. malariae, overall sensitivities were 90.9%, 60.0% and 85.7% respectively. For P.
falciparum and for P. vivax, the sensitivities increased to 100% at parasite densities above 100/μl. The specificity was
100%. The test was easily to perform and the result was stable for at least 1 hour.
Conclusion: The Clearview
® Malaria pLDH was efficient for the diagnosis of malaria. The test was very sensitive for
P. falciparum and P. vivax detection. The sensitivities for P. ovale and P. malariae were better than other RDTs
Background
Malaria is a widespread and life-threatening disease
caused by five species of Plasmodium in humans. Each
year, 2, 200 imported malaria cases are reported to the
French Malaria National Reference Center (FMNRC)
among returned international travellers, and the real
number of cases is estimated at 4, 000 [1]. Prompt diag-
nosis is essential for the treatment and outcome. Tradi-
tional standard diagnosis of malaria is based on
microscopic examination of stained blood smears and it
requires considerable training and experience. Most
laboratories in non-endemic countries lack sufficient
samples to enable building-up and maintenance of
microscopic expertise [2]. Malaria rapid diagnostic tests
(malaria RDTs) may be a complement to microscopic
malaria diagnosis to non-expericenced laboratory staff in
non-endemic setting. Malaria RDTs are immunochro-
matographic tests targeting specific antigens of one or
more Plasmodium species. Among these antigens, the
pLDH (Plasmodium lactate dehydrogenase) is a pan
antigen, produced by all Plasmodium species parasites
that infect humans: its detection allows the diagnosis of
malaria cases whatever the Plasmodium species involved
[3]. Malaria RDTs are available as strips or cassettes,
and the two-band test display visible cherry-red to pur-
ple coloured control and test lines. By now, more than
60 RDT brands and over 200 different products have
been developed. Of those, the World Health Organiza-
tion (WHO) and Foundation for Innovative New Diag-
nostics (FIND) evaluated 70 from 34 manufacturers [4].
Of these products, only six are two-bands tests that
detect pLDH. The Clearview
® malaria pLDH (Orgenics
Ltd, Alere Diagnostics, Yavne, Israel) is a two-band RDT
in a cassette format targeting the pLDH. In this study,
their performance was evaluated with fresh blood sam-
ples of returned international travellers in a reference
centre.
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Study design
The Clearview Malaria pLDH (Orgenics) was evaluated
on fresh blood samples received for analysis and
obtained from international travellers suspected of
malaria. Tests were carried out in the French Malaria
National Reference Centre (FMNRC) in Bichat Hospital
of Paris (France). The reference method was the micro-
scopy performed on the samples. All discordant results
between microscopy and the Clearview Malaria pLDH
test were analysed by polymerase chain reaction (PCR)
and test characteristics were recalculated according to
the PCR-corrected results. The study design was in
compliance with the STARD guidelines for presentation
of diagnostic studies [5].
Samples and materials
Samples are included between July and October 2010
from the collection of fresh venous EDTA-blood sam-
ples received in the laboratory for malaria analysis dur-
ing the study in order to obtain 200 positive samples,
and one hundred of negative samples. The patients were
Europeans travellers returning from malaria-endemic
countries and immigrants returning from visits to their
native countries. Negative samples were obtained from
febrile patients presenting at the outpatient clinic of
Bichat Hospital and positive samples were obtained
from patients diagnosed with malaria and sent by hospi-
tal laboratories to the FMNRC for complementary ana-
lysis in the scope of the national reference laboratory.
Samples were considered as negative if no malaria para-
site was observed by microscopy. The positive selected
panel included samples at varying parasite densities with
the four malaria species (Plasmodium falciparum, Plas-
modium vivax, Plasmodium ovale and Plasmodium
malariae) according to the proportion of each species
observed in France. For P. falciparum,w h i c hi st h e
most frequently retrieved species at FMNRC, a panel
representing the different parasite densities was selected.
Reference method
Microscopy, corrected by PCR, was used as the refer-
ence method. All samples were blindly analyzed by stan-
dard microscopy including species identification and
determination of parasite density. After staining with
Giemsa, thick and thin blood films were examined by an
experienced microscopist in the laboratory. As recom-
mended by the WHO, a slide was considered positive if
at least one asexual form of parasite was detected in 100
microscopic fields in the thick blood film. Blood parasite
density was determined by counting the number of
parasites against between 200 and 1, 000 white blood
cells (WBC) and assuming that each subject had 8, 000
white blood cells/μl of blood. The detection limits of
microscopy in these conditions of reading were eight
parasites per microliter. In case of the presence of P. fal-
ciparum gametocytes alone in the slide, the sample was
not considered as positive. A species-specific PCR analy-
sis as described by Snounou, was performed on all sam-
ples with non-falciparum species to confirm the species
identification by microscopy [6].
Test platform
Clearview
® malaria pLDH is a lateral-flow malaria RDT
in a cassette format. Two lines are present, a control line
which indicates whether the test is valid and a pLDH line
indicates an infection with a Plasmodium spp. According
to the manufacturer’s instructions, Clearview
® malaria
pLDH can detect P. falciparum, P. vivax, P. ovale and P.
malariae. The kits used for the evaluation were stored at
a dry place between 18°C and 25°C.
Test procedure
Tests were performed according to the instructions of
the manufacturer. Samples (5 μl) were loaded with a
transfer pipette (Eppendorf, Le Pecq, France). In case of
the control line did not appear, the result was inter-
preted as invalid and the test was repeated. Readings
were performed 20 minutes after application of the sam-
ple and diluent. A second reading was performed 1 hour
after application of the reagents. Results were scored as
negative (no line visible), or positive (presence of the
test line)(Table 1). If the test line was barely visible, the
result was scored as doubtful. The band strength was
visually compared to the intensity of the control line
a n ds c o r e da sm e d i u mi ft h ei n t e n s i t yo fb o t ht h ec o n -
trol line and the test line were equal, weak if the inten-
sity of the control line was higher than the intensity of
the test line and strong if the intensity of the control
line was lower than the intensity of the test line.
Table 1 interpretation of the Clearview
® Malaria pLDH results according to the microscopy
Microscopy Clearview
® Malaria pLDH Classification of the test
Negative Negative True négative
Positive for malaria (P.f. or P.v. or P. o. or P. m.)* Positive or doubtful True positive
Positive for malaria (P.f. or P.v. or P. o. or P. m.)* Negative False négative
Negative Positive or doubtful False positive
* P.f.: Plasmodium falciparum, P.v.: P. vivax, P.o.: P. ovale, P.m.: P. malariae.
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In case of discordant results between RDT and micro-
scopy (false-negative and false-positive RDT results)
(Table 1), a species specific PCR was performed on both
P. falciparum positive or negative samples [6].
Statistical analysis
Sensitivity and specificity were calculated for overall
Plasmodium species and for each species with 95% con-
fidence intervals (C I). The interpretation of the test
result is shown in Table 1. The test result was consid-
ered as positive with presence of the both control line
and pLDH line, and the test was considered as negative
in case of the presence of the control line alone.
Results
Samples collections
The final panel consisted of 292 samples including
infections with P. falciparum (n = 139), P. vivax (n =
22), P. ovale (n = 20), P. malariae (n = 7), P. falci-
parum and P. ovale (n = 1), P. falciparum and P.
malariae (n = 1), and Plasmodium negative samples (n
= 102) (Table 2). No sample with pure gametocytaemia
was included. These samples were obtained in 292
patients with a male:female ratio of 1.6. The median
age was 35 years (range 2-75). Travellers returned
from Africa (n = 250), Latin America and South Amer-
ica and Caribbean (n = 30) and Asia (n = 12). Most P.
falciparum infections had been acquired in sub-
S a h a r a nA f r i c a( T a b l e2 ) .
Quality control of microscopy results
All PCR performed on samples with discordant results
between RDT and microscopy, confirmed the micro-
scopy results.
Tests characteristics
No invalid test results were observed. Table 3 shows the
test characteristics according to the species identification
and parasite density. The overall sensitivity of the test
and 95% CI for the diagnosis of malaria was 93.2%
[88.3-96.2] (177/190). For P. falciparum, the overall sen-
sitivity was 98.6% [94.9-99.6] (137/139). The sensitivities
for non-falciparum species were 90.9% [72.2-97.4] for P.
vivax (20/22), 85.7% [48.7-97.4] for P. malariae (6/7),
and 60% [38.7-78.1] for P. ovale (12/20).
Parasite densities of false negative samples were com-
prised between 225 and 21, 150 p/μlf o rP. ovale,e q u a l
to 40 or 540 p/μlf o rP. vivax,e q u a lt o9 0 0p / μlf o rP.
malariae,a n de q u a lt o3 2o r6 4p / μlf o rP. falciparum.
For both P. falciparum and P. vivax, the sensitivity
increased to 100% at parasite densities above 100 p/μl.
None of the Plasmodium negative samples was scored
as positive, so the specificity was 100% [95.5-100].
Line intensity reading
For the majority of samples, the positive test line was
read as strong and medium. The line intensity reading
was weak for 11 samples: eight P. falciparum infected
samples with parasite densities comprised between 112
p/μl and 1350 p/μl; two samples infected by P. vivax
with parasite densities equal to 8 p/μl and 900 p/μla n d
one sample infected by P. ovale with a parasite density
equal to 9900 p/μl
Ease of use and stability of the result
The Clearview pLDH test was easily to perform: no dif-
ficulty had been reported to transfer the blood or the
reagent. The clearing of the test strip was good and the
test lines were very easy visualized. The result is stable
for a long time, more than one hour: no positive sample
appeared negative after one hour and inversely, and no
change in the band intensity was observed. The test
instructions in the package insert were scored as clear
and the use of pictures was well appreciated.
Discussion
In this prospective study, the performance of the Clear-
view pLDH test was evaluated on samples obtained in
returned travellers suspected of malaria. Overall sensitiv-
ity for the detection of Plasmodium was 93.2%. For the
detection of P. falciparum, the sensitivity was 98.6%,
Table 2 species distribution, parasite densities and geographical origin of the samples included for the Clearview
®
Malaria pLDH evaluation.
Geography Species identification by microscopy corrected by PCR
P. falciparum
(alone or in association)
P. vivax P. ovale P. malariae No parasites
Africa 139 20 7 84
Asia 4 8
Latin and south America 2 18 10
Parasite density
[median; p/μl]
(range)
123, 762
(32-2, 250, 000)
4, 594
(8-35, 550)
4, 596
(225-21, 150)
2, 083
(135-8, 550)
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100/μl. Overall sensitivities for P. vivax, P. malariae and
P. ovale were 90.9%, 85.7% and 60.0% respectively. No
positive result occurred among the Plasmodium negative
samples.
This study found similar sensitivity of this RDT for
the detection of P. falciparum than a PfHRP2-based
RDT [7]. The advantage of the pLDH test for the diag-
nosis of P. falciparum is the absence of genetic variation
in the pLDH gene [8] in contrast with PfHRP2: samples
of P. falciparum were reported without PfHRP 2 gene in
Amazon [9]. In comparison with RDTs targeting pLDH
included in the WHO/FIND evaluation, the sensitivity
of Clearview
® pLDH is higher for both P. falciparum
and P. vivax detection. In the WHO evaluation, for P.
falciparum, only two tests of the 27 tested products had
a sensitivity higher than 95% at low parasite density
(200 parasites/μl): these tests targeted PfHRP2 [4].
For P. vivax samples at low parasite densities, of the
20 tested, only four products had a sensitivity higher
than 90%.
Similar sensitivity (91.0%) for the detection of P. vivax
was reported in a study in Myanmar with the Malaria
pLDH test (CareStart
® brand) [10]. Ashton et al
reported similar sensitivities with three different tests in
the range of 82.5% to 85.0% observed in Ethiopia [11].
In non-endemic countries, studies evaluating other
RDTs detecting pan-pLDH showed sensitivities of
66.0%, 77.6% or 87.5% for P. vivax detection [12-14].
Studies evaluated the sensitivities for P. malariae and
P. ovale are few and in all cases, sensitivities for detec-
tion of these species were poor. Few RDT tests had sen-
sitivity for the detection of P. malariae higher than 80%,
like the Clearview
® test. Previous studies performed in
non endemic setting, reported sensitivities for detection
of P. malariae with a pLDH based RDT test between
30.4% [13] and 45.2% [14].
The Clearview
® pLDH test is better than more of the
RDT tests for the detection of P. ovale despite a false-
negative result with a high parasitaemia (21, 150 p/μl)
confirmed after repeating the RDT. A lack of pLDH
production by the involved parasite could explain this
result as demonstrated for PfHRP2 in P. falciparum
[15]. Genotype analysis could be performing to confirm
this hypothesis. For this species diagnosis, recent studies
reported 5.5% for the Palutop +4 [12] or 18.4% for the
CareStart
® Malaria Pf/pan [13]. The best test seemed to
be the SD FK60 Malaria Ag Pf/Pan test with a sensitivity
of 76.3% [14].
The specificity of the test is excellent: no false positive
result was observed. Especially, the advantage of the
pLDH detection is the clearance of the protein after
anti-malarial treatment, so no false positive result was
observed in treated patient like with PfHRP2 RDT based
test [16].
This evaluation of the RDT in a reference setting give
data before using in a hospital setting in a developed
country. Evaluation in the field would be necessary to
confirm these performances in other circumstances.
The test was easily to perform with good clearing of
the background. The line intensity was stable in time,
more than one hour. The small volume of blood used to
perform the test is an advantage especially when the test
is performed with capillary blood from children regard-
ing to the difficulties in collecting blood from young
children. Most of RDT needs at least 10 μlo fb l o o dt o
perform the test.
Conclusions
The Clearview
® pLDH test is very specific and sensi-
tive test for all Plasmodium species responsible of
imported malaria in France. The sensitivity for the
detection of P. ovale is medium but better than other
RDT tests available in France. The test is easily to per-
form and result could be re-read a long time after it
had been performed, which is very important to con-
trol results, for example those obtained during night-
duty.
Table 3 specificity and sensitivity of Clearview
® Malaria pLDH for the detection of all Plasmodium species.
Microscopic examination (confirmed by PCR) Clearview Malaria pLDH Specificity
(95 CI%)
Sensitivity
(95 CI%)
positive negative
Negative 102 100% (96.4-100)
Positive P. falciparum 137 2 98.6% (94.9-99.6)
Positive P. vivax 20 2 90.9% (72.2-97.5)
Positive P. ovale 12 8 60.0% (38.7-78.1)
Positive P. malariae 6 1 85.7% (48.7-97.4)
P. falciparum and P. malariae 1 ND*
P. falciparum and P. ovale 1 ND*
* ND: not determined
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